VAISHALI Stock Overview
Engages in the pharmaceutical business in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Vaishali Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹156.78 |
| 52 Week High | ₹203.60 |
| 52 Week Low | ₹114.85 |
| Beta | 0.37 |
| 11 Month Change | 10.33% |
| 3 Month Change | 8.24% |
| 1 Year Change | 25.32% |
| 33 Year Change | 255.91% |
| 5 Year Change | 587.25% |
| Change since IPO | 303.94% |
Recent News & Updates
Here's Why Vaishali Pharma (NSE:VAISHALI) Has Caught The Eye Of Investors
Jan 17
Vaishali Pharma Limited's (NSE:VAISHALI) Shares Leap 30% Yet They're Still Not Telling The Full Story
Dec 18Is Vaishali Pharma (NSE:VAISHALI) A Risky Investment?
Dec 11Recent updates
Here's Why Vaishali Pharma (NSE:VAISHALI) Has Caught The Eye Of Investors
Jan 17Vaishali Pharma Limited's (NSE:VAISHALI) Shares Leap 30% Yet They're Still Not Telling The Full Story
Dec 18Is Vaishali Pharma (NSE:VAISHALI) A Risky Investment?
Dec 11We Ran A Stock Scan For Earnings Growth And Vaishali Pharma (NSE:VAISHALI) Passed With Ease
Oct 04With EPS Growth And More, Vaishali Pharma (NSE:VAISHALI) Makes An Interesting Case
Feb 04Vaishali Pharma (NSE:VAISHALI) Seems To Use Debt Quite Sensibly
Dec 10We Ran A Stock Scan For Earnings Growth And Vaishali Pharma (NSE:VAISHALI) Passed With Ease
Aug 20Should You Be Adding Vaishali Pharma (NSE:VAISHALI) To Your Watchlist Today?
May 19These 4 Measures Indicate That Vaishali Pharma (NSE:VAISHALI) Is Using Debt Reasonably Well
Feb 10A Look At The Intrinsic Value Of Vaishali Pharma Limited (NSE:VAISHALI)
Aug 17A Look At The Fair Value Of Vaishali Pharma Limited (NSE:VAISHALI)
May 17Are Vaishali Pharma Limited's (NSE:VAISHALI) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Mar 17Calculating The Fair Value Of Vaishali Pharma Limited (NSE:VAISHALI)
Feb 15Does Vaishali Pharma (NSE:VAISHALI) Have A Healthy Balance Sheet?
Jan 19
Are Vaishali Pharma Limited's (NSE:VAISHALI) Mixed Financials Driving The Negative Sentiment?
Nov 23Shareholder Returns
| VAISHALI | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 4.2% | 0.9% | 1.1% |
| 1Y | 25.3% | 46.8% | 44.4% |
Return vs Industry: VAISHALI underperformed the Indian Pharmaceuticals industry which returned 46.8% over the past year.
Return vs Market: VAISHALI underperformed the Indian Market which returned 44.4% over the past year.
Price Volatility
| VAISHALI volatility | |
|---|---|
| VAISHALI Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in IN Market | 9.6% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: VAISHALI has not had significant price volatility in the past 3 months.
Volatility Over Time: VAISHALI's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 27 | Hemanth Pathak | www.vaishalipharma.com |
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers active pharmaceutical ingredients (APIs), including antibiotics, anti-ulcer, anti-inflammatory/analgesic/anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, anti-diarrheal/anti-protozoal/anti-parasitic, anti-viral, anti-epileptic, anti-asthmatic, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helmintic drugs, as well as excipients, topical steroids, corticosteroids, and enzymes. The company also provides formulation products, such as laxative, anti-ulcer/enzyme, anti-asthmatic, anti-viral, anti-psychotic, vitamins, and other formulations.
Vaishali Pharma Limited Fundamentals Summary
| VAISHALI fundamental statistics | |
|---|---|
| Market cap | ₹1.68b |
| Earnings (TTM) | ₹7.19m |
| Revenue (TTM) | ₹862.80m |
233.8x
P/E Ratio1.9x
P/S RatioIs VAISHALI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VAISHALI income statement (TTM) | |
|---|---|
| Revenue | ₹862.80m |
| Cost of Revenue | ₹744.16m |
| Gross Profit | ₹118.64m |
| Other Expenses | ₹111.45m |
| Earnings | ₹7.19m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.67 |
| Gross Margin | 13.75% |
| Net Profit Margin | 0.83% |
| Debt/Equity Ratio | 29.4% |
How did VAISHALI perform over the long term?
See historical performance and comparison